Patient genotypes impact survival after surgery for isolated congenital heart disease

Daniel Seung Kim1, Jerry H Kim2, Amber A Burt3

  • 1Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Seattle, Washington; Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington.

Insights

Genetic variations in vascular endothelial growth factor A and superoxide dismutase 2 influence survival after infant cardiac surgery. Infants with high-risk alleles face a significantly increased risk of death or heart transplant.

Area of Science:

  • Cardiovascular Surgery
  • Genetics
  • Pediatrics

Background:

  • Infant survival post-cardiac surgery depends on oxidative stress and vascular regulation.
  • Genetic variations in these pathways may impact outcomes in congenital heart disease.

Purpose of the Study:

  • To investigate the association between genetic variations in oxidative stress and vascular response pathways and postoperative survival.
  • To test the hypothesis that genetic polymorphisms influence survival in infants with nonsyndromic congenital heart disease.

Main Methods:

  • Analysis of a cohort of 422 infants undergoing cardiac surgery before 6 months of age.
  • Genotyping of six single nucleotide polymorphisms (SNPs) in key genes.
  • Cox proportional hazard models used to assess effects on transplant-free survival, adjusting for covariates.

Main Results:

  • Specific SNPs in vascular endothelial growth factor A (rs833069) and superoxide dismutase 2 (rs2758331) were significantly associated with long-term survival.
  • A cumulative risk score based on these SNPs demonstrated an additive effect, with higher scores correlating with worse transplant-free survival.
  • Patients with the highest risk score (4 risk alleles) had a 15.64-fold increased hazard for adverse outcomes.

Conclusions:

  • Genetic variants in VEGFA and SOD2 are significant modifiers of survival after infant cardiac surgery.
  • Infants homozygous for high-risk alleles in both genes face a substantially elevated risk of death or heart transplant.
  • These findings highlight the role of genetic predisposition in surgical outcomes for congenital heart disease.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
460
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
804
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
120